Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Notaflipper wrote "Getting CE-IVD accreditation is one thing, selling is another, and the route to commercialisation is not cheap"
I'm not saying it could go the same way, but I believe GDR may have learned a lesson here and have now employed an in-house sales team which was missing before.
The AIHL launch should also be a success because they have at least one captive customer (NHS) and a very good sales partner in Inspiration Healthcare. But, then again I still have my fingers and toes crossed lol!
@HotChip
The Punit and £2 thing is a long term joke on this BB, not a serious post lol.
Good to see you're still optimistic there Punit ;)
Islandgirl said
"One of the quickest and most accurate POC PCR tests to be approved for EU use in 10 days."
POC not PCR, it is LAMP.
The Genedrive lab PCR test is one of the fastest & accurate available and is already commercially available but has not yet had any significant sales.
Davemcmanus wrote "Your post is just silly"
You're quite right Dave! Lol.
It was only meant to try and crack a teeny weeny smile on this poor BB's dour face.
I think this last year's performance of GDR has scarred a few of the longer term holders here so that any news whatsoever is met with "we're all dooomed!" lol.
How about we look at this particular piece of news with a different slant.
Here's my thinking.. how about we picture the following (imaginary) scenario ....
One of the reasons we performed badly is because the outgoing CFO wasn't strong enough to insist that other markets needed to be exploited and a stronger sales force required otherwise the company would be in financial shortfall. How about he wasn't authoritative enough to ask Mr B (and others) to justify salaries and bonuses without demonstrating significant sales, especially so soon after a prior 9mths of share dilution and a cash raise.
How about he didn't make the right choices as the company transformed from a research to a commercial footing in his 5yr tenure.
I'm not saying any of these are true. I'm just hypothesizing with my meandering mind.
Now how about we now say that the new CFO sweeps in and revolutionises the company's finances - make it more efficient and saves money in new ways. Galvanizes the sales force, is an all round a better captain of finance, puts fire into a staid board and maximises shareholder value. Whoosh!
The right appointment could make seriously make an enormous difference here, especially if correctly incentivised.
So maybe we're not "dooomed" after all....
Interesting programme long chat with CEO Warren East on this morning's Radio 5 "Wake Up To Money".
Mentions the full gamut of RR's products and developments including hybrid trains/planes micro grids and SMR.
https://www.bbc.co.uk/programmes/m00113dw
Should hopefully be available on catch up later - worth a listen.
I believe there may be a little confusion here.
PCR tests for AIHL may have been around for a while. The gene causing AIHL was identified back in 1993.
However, when a baby arrives into a unit and needs antibiotics immediately, there is not enough time to carry out the current test format and receive the result. Current strategies for monitoring this gene take upto 2wks within the NHS and the NHS alone has approx 90,000 such urgent admissions a year. So to quote a PALOH tweet "current tests are useless in this acute setting"
Hence why Genedrive (the company) were asked to develop an assay to use with their Genedrive (the device) to get an accurate result within the 'golden hour' for sepsis and which could be performed in-situ, without specialist staff and be non-invasive (cheek swab) - PALOH study.
But, I'm willing to listen if I've got the wrong end of the stick...
GarryGraham said:
"
Am I correct in assuming the government has guaranteed £150m towards Small Nucleur Reactors. This seems a drop in the ocean in comparison to other green energies such as wind turbines."
My understanding from an interview yesterday with the head of the consortium is that the £120m announced recently by the government is only for the next stage of the strategy which is 'enabling deployment' i.e. location/site assessments.
The next stage of project finance should be announced prior to COP26.
I believe the exchange rate will be fixed at the date of purchase (probably by TUI broker handling the RI). This would be similar to when dividends are quoted in € or $. I think the variety of £ being quoted is just shareholder's brokers making sure you have sufficient to cover e.g. my broker wrote this in their email -
"We don’t know the exact sterling cost yet. We’re asking you to make 190p available for each share you wish to buy."
Maybe those who partook in the previous RI can confirm. I find it hard to believe everyone could be charged differently.
IMHO
I did partake (partially) and had this email from my broker (HL) on 15th October @4pm (this last Friday) -
"The Open Offer has now been completed. All Elections have been satisfied in full.
.......
The resulting Shares have now been issued. As a result your 'account' has been updated"
So I believe the shares have been admitted. May be there'll be a confirmation RNS on Monday.
Have a look here.....
https://www.investopedia.com/investing/understanding-rights-issues/
HTH
* not yet received
'TUI AG Tradable Rights' has appeared in my Hargreaves Lansdown account, although they say they have yet received the Key Investor Information Document yet when you click on it.
Bass
iParsnip wrote "When we buy the RI shares how soon before we see the full value in our accounts again?"
See Rights Issue timetable - prospectus/website etc.
* Upto Oct 26 is the 'Subscription Period'.
* Nov 2nd "Commencement of trading in the New Shares
Settlement of New Shares with shareholders and investors"
HTH
Seems a lot of confusion about entitlement and dates.
I received this from HL Hargreaves Lansdown) on 7th Oct
"TUI AG has announced plans to improve its financial resilience in today’s tough economic climate.
Part of the plan is to allow shareholders to buy 10 new shares for every 21 existing shares at a price of EUR2.15 per share. This is called a rights issue and it’s a common way for companies to raise money.
You don’t need to do anything now.
All TUI shareholders at the end of today will qualify for the rights issue. Once the qualifying point passes, it’s normal for the company’s share price to drop. This is because shareholders will get the rights, which also have a value.
We’ll be in touch with more information from 12 October, once we’ve received your new rights, including how to take part."
So LSE share do qualify and it is now past the date to receive the Rights.
HTH
This may help explain it to some (incl. A little video). The investopedia website is quite handy resource for info and terminology explanations.
https://www.investopedia.com/investing/understanding-rights-issues/
Hi, for those who are unsure about how they take part in the rights issue, I have now received notification from my broker (HL).
Quote:
"You don’t need to do anything now.
All TUI shareholders at the end of today will qualify for the rights issue. Once the qualifying point passes, it’s normal for the company’s share price to drop. This is because shareholders will get the rights, which also have a value.
We’ll be in touch with more information from 12 October, once we’ve received your new rights, including how to take part."
HTH GLA
@Hex & @beat ty
Can someone please clarify this figure of a corrected 280-290pps that is being used here?
RNS 06-10:
I understand the theoretical discount on the rights issue is 35.1% giving a RI price of E2.15pps. This gave the full share Euro DAX price of E3.30
Current LSE is in a range of 330-345pps (say). 35% discount would equate to 214-221pps.
So how has 280pps (approx) been arrived at? Or is that the assumed value based on Market Cap if all RI shares are taken up?
I also note that in a later RNS that the base price is now quoted at E3.60pps.
Apologies for my ignorance :)